Tuesday, November 24, 2009, 5:19AM AEST - The Australian Stockmarket opens in 4 hours and 41 minutes.
To create a watchlist or portfolio of shares, Register

GenVec Inc. (GNVC)

5:03AM AEST: 0.9305 USD  Up 0.0506 (5.75%)  
 MORE ON GNVC 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 GenVec, Inc. (NGM:GNVC) Delayed quote dataEdit
Last Trade:0.9305 USD
Trade Time: 5:03AM AEST
Change:Up 0.0506 (5.75%)
Prev Close:0.8799
Open:0.89
Bid:0.9308 x 100
Ask:0.94 x 3900
1y Target Est:2.00
Day's Range:0.85 - 0.96
52wk Range:0.30 - 1.17
Volume:1,368,465
Avg Vol (3m):1,861,710
Market Cap:98.94M
P/E (ttm):N/A
EPS (ttm):-0.221
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add GNVC to Portfolio   Download Data

 HEADLINES 
[$$] Biotech Stock Mailbag: Cardium Therapeutics
at RealMoney by TheStreet.com (Fri, Nov 13)
GENVEC INC Financials
EDGAR Online Financials (Thu, Nov 12)
New Star Analyst Rankings for GenVec, Inc.
StarMine (Mon, Nov 9)
GENVEC INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Sat, Nov 7)
GenVec, Inc. Earnings Call scheduled for 10:00 am ET today
CCBN (Sat, Nov 7)
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
EDGAR Online (Fri, Nov 6)
GenVec Reports Third Quarter 2009 Financial Results
PR Newswire (Fri, Nov 6)
GenVec signs $22 mln vaccine contract, shares up
at Reuters (Fri, Nov 6)
GenVec Signs New Contract to Support HIV and Influenza Vaccine Development
PR Newswire (Thu, Nov 5)
Q3 2009 GenVec, Inc. Earnings Release - After Market Close
CCBN (Thu, Nov 5)
More Headlines for GNVC...

 ANALYST 
EPS Est (next year) (Dec-09) :-0.17
EPS Est (in 2 years) (Dec-10) :-0.18
Avg Rec (current)*:2.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
GenVec, Inc., a clinical stage biopharmaceutical company, develops gene-based therapeutic drugs and vaccines in the United States. Its lead therapeutic product candidate, TNFerade biologic, is under Phase III trial for first-line treatment of inop...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices